This study not only uncovers IL-27 as a critical modulator of MSC immune plasticity but also provides a foundation for developing IL-27-enhanced MSC2 as an innovative therapeutic modality applicable to LN and other autoimmune disorders. The gene discussed is IL27; the disease is lobular neoplasia.